A single study on abemaciclib revealed nonsignificant differences (HR 1.30; 95%CI from 0.53 to 3.19), with similar results for OS.<h4>Conclusions</h4>PPI use in HR + /HER2- breast cancer patients treated with palociclib should be avoided. Here, ERBB2 is linked to breast carcinoma.